31.82
Tg Therapeutics Inc stock is traded at $31.82, with a volume of 2.06M.
It is up +5.29% in the last 24 hours and up +7.28% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
See More
Previous Close:
$30.22
Open:
$30.53
24h Volume:
2.06M
Relative Volume:
1.01
Market Cap:
$5.08B
Revenue:
$616.29M
Net Income/Loss:
$447.18M
P/E Ratio:
11.46
EPS:
2.7771
Net Cash Flow:
$-24.99M
1W Performance:
+5.93%
1M Performance:
+7.28%
6M Performance:
-8.14%
1Y Performance:
-25.65%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TGTX
Tg Therapeutics Inc
|
31.82 | 4.83B | 616.29M | 447.18M | -24.99M | 2.7771 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
US$750 Million Credit Facility Could Be A Game Changer For TG Therapeutics (TGTX) - simplywall.st
A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility - Yahoo Finance UK
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co. - MarketBeat
Day Trade: Is TG Therapeutics Inc still a buy after recent gains2026 Review & Stepwise Trade Execution Plans - baoquankhu1.vn
CapEx per share of TG Therapeutics, Inc. – MIL:1TGTX - TradingView
(TGTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TG Therapeutics (TGTX) reports financial results for Q4 and full year 2025 - MSN
TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention - Sahm
TG Therapeutics, Inc. (TGTX) Enters $750 Million Term Loan Agreement – SEC 8-K Filing Summary - Minichart
Form 8K TG Therapeutics Inc For: 20 March By Investing.com - Investing.com Canada
TG Therapeutics Files Procedural 8-K on Financial Obligation - TipRanks
Form 8K TG Therapeutics Inc For: 20 March - Investing.com
TG Therapeutics (TGTX) secures $750M 2026 Term Loan maturing 2031 - Stock Titan
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 earnings call transcript - MSN
TG Therapeutics (TGTX) Secures $750 Million Credit Facility - GuruFocus
1TGTX.MI Earnings History & Surprises | EPS & Revenue Results | TG THERAPEUTICS INC (BIT:1TGTX) - ChartMill
TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com - Investing.com India
TG Therapeutics board expands share repurchase program to $300M - TipRanks
TG Therapeutics secures $750M credit facility with Blue Owl - Investing.com
TG Therapeutics (TGTX) Secures $750M Credit Facility, Expands Sh - GuruFocus
TG Therapeutics Receives $500 Million in New Capital From Blue Owl, Increases Share Buyback - marketscreener.com
TG Therapeutics secures an additional $500 million in non-dilutive capital from Blue Owl and expands share repurchase program to $300 million - marketscreener.com
TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million - TradingView
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million - The Manila Times
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital From Blue Owl and Expands Share Repurchase Program to $300 Million - 富途牛牛
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
Is the options market predicting a spike in TG Therapeutics stock? - MSN
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects - timothysykes.com
TG Therapeutics (NASDAQ:TGTX) Shares Up 7.9%Here's What Happened - MarketBeat
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story - simplywall.st
TGTX SEC FilingsTg Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TGTX Q4 earnings lag estimates, Briumvi sales drive top line - MSN
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
Data Published in Neurology and Therapy Demonstrate - GlobeNewswire
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):